Ebola vaccine trial offers hope amid deadly DRC outbreak

What the report says

A vaccine study called Tumaini is set to begin soon in the Democratic Republic of the Congo as health officials race to contain an Ebola Bundibugyo outbreak that has caused thousands of reported cases and deaths across several provinces. According to The Independent Uganda, the trial is waiting for final regulatory and ethics approvals, with the first doses expected this week in Kinshasa. The study will initially use Ervebo, a vaccine developed for the Zaire strain of Ebola, while two candidates designed for the Bundibugyo strain may be added later.

The report says the World Health Organisation is still assessing whether Ervebo can offer enough cross-protection against the Bundibugyo virus. DRC researchers and WHO officials said transmission appears to be slowing in Ituri, the outbreak’s epicentre, although the disease remains a serious public health threat, especially because many patients are dying outside health facilities.

The article also places the trial in a regional context. It notes concern about possible spread beyond the DRC, with cases or investigations reported in Uganda, Kenya and Nigeria. Uganda has said its own outbreak has ended, while WHO and national authorities continue contact tracing and surveillance elsewhere. The report adds that treatment research is also under way, including a clinical trial of an antibody cocktail and remdesivir, as officials look for better tools to reduce deaths and limit further spread.